If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Five years ago, pharmaceutical company (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking to make such a bet.
Then the COVID-19 pandemic materialized. As it turns out, the coronavirus was the ideal target for Moderna's biotechnology. In December 2020, the U.S. Food and Drug Administration approved its COVID vaccine for emergency use. Other nations' regulatory bodies followed suit.
The rest, as they say, is history.
Source Fool.com
Moderna Inc. Aktie
153,60 €
1,36 %
Positive Stimmung für Moderna Inc. mit mehreren Buy- gegenüber Sell-Einschätzungen.
Allerdings ergibt sich ein Potenzial von -2.34% für Moderna Inc., da das Kursziel von 150 € unter dem aktuellen Kurs von 153.6 € liegt.
